Nyxoah SA 

€2.9
25
+€0.25+9.43% Today

Statistics

Day High
2.86
Day Low
2.86
52W High
7.51
52W Low
2.28
Volume
-
Avg. Volume
-
Mkt Cap
108.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.74
-0.65
-0.57
-0.48
Expected EPS
-0.58649700699
Actual EPS
N/A

Financials

-1,310.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.04MRevenue
-118.47MNet Income

Analyst Ratings

$7.59Average Price Target
The highest estimate is 8.35.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5YI.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Inspire Medical Systems
INSP
Mkt Cap1.58B
Inspire Medical Systems, Inc. offers an alternative obstructive sleep apnea treatment, directly competing with Nyxoah's hypoglossal nerve stimulation technology.
Medtronic
MDT
Mkt Cap111.22B
Medtronic plc provides various medical technologies, including sleep therapy devices that compete in the broader sleep apnea market.
Resmed
RMD
Mkt Cap32.71B
ResMed Inc. specializes in cloud-connectable medical devices for sleep apnea, directly competing in the sleep disorder market.
Koninklijke Philips N.V.
PHG
Mkt Cap25.99B
Koninklijke Philips N.V. offers sleep and respiratory care solutions, competing in the sleep apnea device market.
Zimmer Biomet
ZBH
Mkt Cap18.01B
Zimmer Biomet Holdings, Inc. is a competitor in the medical device sector, with products that can indirectly compete in the sleep apnea market.
Stryker
SYK
Mkt Cap126.97B
Stryker Corporation is involved in medical technologies, including products for sleep disorders, indirectly competing with Nyxoah.
Boston Scientific
BSX
Mkt Cap93.36B
Boston Scientific Corporation develops medical devices that, while not directly competing, offer alternative treatments in the broader market of sleep disorders.
Edwards Lifesciences
EW
Mkt Cap47.07B
Edwards Lifesciences Corporation is known for its patient-focused medical innovations, which include treatments that could indirectly compete in the sleep apnea space.
Abbott Laboratories
ABT
Mkt Cap178.76B
Abbott Laboratories offers a wide range of healthcare solutions, including devices for cardiovascular and neuromodulation, indirectly competing in the sleep disorder market.
Globus Medical
GMED
Mkt Cap11.89B
Globus Medical, Inc. is a medical device company that, while focusing on musculoskeletal solutions, competes in the broader medical device market against companies like Nyxoah.

About

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Show more...
CEO
Mr. Robert Taub MBA
Employees
183
Country
DE
ISIN
BE0974358906
WKN
000A2QCWK

Listings

0 Comments

Share your thoughts

FAQ

What is Nyxoah SA stock price today?
The current price of 5YI.F is €2.9 EUR — it has increased by +9.43% in the past 24 hours. Watch Nyxoah SA stock price performance more closely on the chart.
What is Nyxoah SA stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nyxoah SA stocks are traded under the ticker 5YI.F.
Is Nyxoah SA stock price growing?
5YI.F stock has risen by +27.47% compared to the previous week, the month change is a -3.49% fall, over the last year Nyxoah SA has showed a -44.23% decrease.
What is Nyxoah SA market cap?
Today Nyxoah SA has the market capitalization of 108.88M
When is the next Nyxoah SA earnings date?
Nyxoah SA is going to release the next earnings report on May 12, 2026.
What were Nyxoah SA earnings last quarter?
5YI.F earnings for the last quarter are -0.59 EUR per share, whereas the estimation was -0.55 EUR resulting in a -7.62% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Nyxoah SA revenue for the last year?
Nyxoah SA revenue for the last year amounts to 9.04M EUR.
What is Nyxoah SA net income for the last year?
5YI.F net income for the last year is -118.47M EUR.
How many employees does Nyxoah SA have?
As of April 07, 2026, the company has 183 employees.
In which sector is Nyxoah SA located?
Nyxoah SA operates in the Health Care sector.
When did Nyxoah SA complete a stock split?
Nyxoah SA has not had any recent stock splits.
Where is Nyxoah SA headquartered?
Nyxoah SA is headquartered in Mont-Saint-Guibert, DE.